{"id":"hcp1904-3","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL4297976","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GLP-1 receptor agonists mimic the glucagon-like peptide-1 hormone, which stimulates insulin secretion in response to elevated blood glucose levels while simultaneously suppressing glucagon secretion. The long-acting formulation of HCP1904-3 allows for less frequent dosing while maintaining sustained therapeutic effects on blood glucose regulation.","oneSentence":"HCP1904-3 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:55.584Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05407220","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2022-06-29","conditions":"Healthy","enrollment":16},{"nctId":"NCT05199129","phase":"PHASE3","title":"Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2021-11-17","conditions":"Hypertension","enrollment":166}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HCP1904-3","genericName":"HCP1904-3","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HCP1904-3 is an intervention being studied in a clinical trial for its pharmacokinetics, safety, and tolerability in healthy male volunteers. The conditions being studied in this trial include hypertension and healthy individuals.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}